

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



CSPC PHARMACEUTICAL GROUP LIMITED

石藥集團有限公司

(Incorporated in Hong Kong with limited liability)

(Stock Code: 1093)

VOLUNTARY ANNOUNCEMENT

GLP-1/GIP RECEPTOR DUAL-BIASED AGONIST POLYPEPTIDE INJECTION (SYH2069 INJECTION) OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.

The Board of Directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that GLP-1/GIP receptor dual-biased agonist polypeptide injection (SYH2069 Injection) (the “**Product**”) developed by the Group has obtained approval from the U.S. Food and Drug Administration (FDA) to conduct clinical trials in the U.S.

With the potential to become China’s first GLP-1/GIP receptor dual-biased agonist to enter clinical development, the Product can selectively activate the cAMP pathway and markedly reduce β -arrestin recruitment, thereby decreasing receptor internalization and desensitization, enhancing drug efficacy, and extending the durability of effect. Furthermore, through the integration of long half-life modification platform technology, the Product can achieve more profound and sustained weight loss effects. In studies involving diet-induced obesity (DIO) mice and non-human primates, the Product demonstrated significantly superior efficacy on weight loss and metabolic improvement compared to similar marketed products. Repeat-dose toxicology studies in non-human primates indicated that the Product was well-tolerated, with no vomiting and gastrointestinal adverse reactions observed. With its outstanding efficacy and good safety profile, the Product is expected to become a new-generation therapeutic agent for overweight/obesity and other metabolic diseases.

The indication for this clinical trial approval is weight management for individuals with obesity or overweight and at least one weight-related comorbidity. In addition, the Product also has the potential to improve glycemic control in adults with type 2 diabetes mellitus (T2DM), providing a promising clinical development value.

By order of the Board
CSPC Pharmaceutical Group Limited
CAI Dong Chen
Chairman

Hong Kong, 5 December 2025

As at the date of this announcement, the Board comprises Mr. CAI Dong Chen, Mr. ZHANG Cuilong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. YAO Bing, Mr. CAI Xin, Mr. CHEN Weiping and Mr. QU Zhiyong as Executive Directors; and Mr. WANG Bo, Mr. CHEN Chuan, Prof. WANG Hongguang, Mr. AU Chun Kwok Alan, Mr. LAW Cheuk Kin Stephen and Ms. LI Quan as Independent Non-executive Directors.